I attended HIMSS17 this year on a mission to learn about how providers have applied genomics and precision medicine to their workflows and the implications for IT departments. While the market for precision medicine has great potential in the next 3-5 years, there were few vendors and only a handful of sessions on this topic. My take is that it will be 2-3 years before precision medicine becomes more of a focal point for the industry.
With that said, below are three key takeaways from the conference that can help industry professionals better understand how to bring precision medicine into the mainstream of the healthcare ecosystem:
In addition to the key takeaways above, there was the usual discussion at HIMSS17 related to the ethics of genetic testing and the fact that, as a result of having genetic testing performed, patients may be unable to obtain life insurance and long term care insurance. While these barriers are very real today, there will likely be a regulatory framework that is developed in the future which will allow patients to receive genetic testing without fear of losing the ability to purchase insurance. This is the single most important development needed to popularize precision medicine within the healthcare industry to selectively prescribe drugs-based efficacy in individuals.